Abstract: The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

Abstract: Compounds having herbicidal activity effective against economically important harmful plants are disclosed. The disclosed compounds exhibit herbicidal activity even at relatively low application rates, while at the same time may exhibit compatibility with crop plants. The disclosed compounds may further be effective and efficient against a large number of weeds and against a broad spectrum of weed grasses. As disclosed herein, 3-phenylisoxazoline-5-carboxamides of S-containing cyclopentenylcarboxylic esters of formula (I) and their salts exhibit herbicidal activity against a broad spectrum of economically important mono- and dicotyledonous annual harmful plants.

Abstract: What are described are compounds of the general formula (I) and agrochemically acceptable salts thereof and their preparation and their use in the crop protection sector.

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: The present invention provides a composition comprising a biologically pure culture of a Paenibacillus sp. strain comprising a mutant DegU lacking a functional receiver domain or a functional DNA binding domain and/or a mutant DegS lacking a functional single binding domain or a functional ATPase domain with decreased viscosity in a liquid culture. Also provided is a method of identifying a Paenibacillus sp. mutant derivative strain with decreased viscosity in a liquid culture compared to a Paenibacillus sp. parental strain with a visual screen for mutant isolates with a non-mucoid morphology.

Abstract: The present application provides a CRISPR/Cas system comprising a nuclease segment that encodes a Cas9 nuclease or variant thereof, a guide RNA segment comprising a nucleotide sequence that encodes a gRNA or sgRNA, and a promoter segment comprising a nucleotide sequence that encodes a first promoter comprising one or more tetracycline operator sequence, wherein the gRNA segment is operably linked to the promoter segment. The present application also provides materials and methods for controlling transcriptional expression of guide RNAs and/or post-transcriptional expression of Cas nuclease.

Abstract: The present invention provides compositions comprising herbicidally active compounds (A) and (B), where (A) represents one or more compounds of the general formula (I) or their agrochemically acceptable salts [component (A)], and (B) represents one or more herbicides [component (B)]. The application furthermore relates to a method and to the use of the herbicidal composition according to the invention for controlling harmful plants or for regulating growth.

Abstract: The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ?60%, ?70%, ?80%, or ?90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ?10 nM, ?5 nM, ?2.

Abstract: The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

Abstract: A fluid injector system includes a control device operably associated with at least one drive component for use in actuating a plurality of fluid containers in fluid communication with a patient through an administration line. The control device includes at least one processor programmed or configured to enable programming of a diagnostic injection protocol comprising one or more phases according to which at least one of the first and the second fluid containers are selectively actuatable by the at least one drive component to enable injection of at least one of a first fluid and a second fluid into the patient. The control device is further programmed or configured to enable selection and commencement of at least partial preloading into the administration line of at least one of the first fluid and the second fluid in accordance with the one or more phases of the diagnostic injection protocol.

Abstract: The present invention covers furoindazole compounds of general formula (I): in which R1, R2, R3, R4, R5, R6a and R6b are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitu

Abstract: A fluid injector system for use in administering to a patient a fluid in an injection protocol in connection with a diagnostic imaging procedure includes at least one display and a control device. The control device is programmed to determine, for each of the injection protocols performed by the fluid injector system, a component status for the at least one disposable component. The component status indicates whether use of the at least one disposable component was compliant with instructions for use applicable to the at least one disposable component. The control device is further programmed to enable the at least one display to display a compliance report. The compliance report includes one or more visual indicators providing visual feedback about compliance with the instructions for use based on the component status determined for each of the injection protocols performed using the fluid injector system.

Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Abstract: The following disclosure relates to the field of data analysis, in particular medical data analysis, or more particularly relates to systems, apparatuses, and methods for processing in particular medical data stored in different modalities, so-called multi-modal data. In some embodiments, the disclosure relates to similarity retrieval for input data, in particular medical input data.

Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Abstract: The present invention provides a method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I), characterized in that the intermediate 4-hydroxy-5-methyl-1H-pyridin-2-one of the formula (III) is reacted with ammonia in an autoclave with addition of an ammonium bromide salt.

Abstract: * combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B: anti-Programmed Cell Death Protein 1 (also referred to as “PD-1” or “CD279” (cluster of differentiation 279)) antibody (anti-PD-1 mAb) as defined herein; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially; independently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; and * a kit comprising such a combination.

Abstract: The present disclosure deals with the quickening of MRI examinations. Subjects of the present disclosure are a method, a system, a computer program product, a use, a contrast agent for use and a kit.

Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.

Abstract: The present invention relates to an aerial vehicle (10). aerial vehicle comprises a liquid chemical tank (20), at least one liquid spray unit (30), at least one actuator (40), a plurality of sensors (50), and a processing unit (60). The liquid chemical tank is configured to hold a liquid chemical. The at least one liquid spray unit is configured to spray the liquid chemical. The at least one actuator is configured to operate the at least one liquid spray unit. At least one sensor (51) of the plurality of sensors is configured to measure a speed of the aerial vehicle relative to the ground. At least one sensor (52) of the plurality of sensors is a light detection and ranging (LIDAR) sensor configured to measure the direction and distance of airborne particles relative to the aerial vehicle with respect to a fore-aft axis of the aerial vehicle.